There were also no differences between the groups regarding anemia therapy (erythropoietin stimulating agents, and iron) and CKD-MBD treatment (paricalcitol, vitamin D3, use and type of phosphate binders). The gene discussed is EPO; the disease is Marchiafava-Bignami disease.